BRCA1 and BRCA2 mutations in breast and ovarian cancer families from south west Colombia
Abstract
Introduction: Breast cancer is the most common neoplasia of women from all over the world especially women from Colombia. 5%10% of all cases are caused by hereditary factors, 25% of those cases have mutations in the BRCA1/BRCA2 genes.
Objective: The purpose of this study was to identify the mutations associated with the risk of familial breast and/or ovarian cancer in a population of Colombian pacific.
Methods: 58 high-risk breast and/or ovarian cancer families and 20 controls were screened for germline mutations in BRCA1 and BRCA2, by Single Strand Conformation Polymorphism (SSCP) and sequencing.
Results: Four families (6.9%) were found to carry BRCA1 mutations and eight families (13.8%) had mutations in BRCA2. In BRCA1, we found three Variants of Uncertain Significance (VUS), of which we concluded, using in silico tools, that c.8112C>G and c.3119G>A (p.Ser1040Asn) are probably deleterious, and c.3083G>A (p.Arg1028His) is probably neutral. In BRCA2, we found three variants of uncertain significance: two were previously described and one novel mutation. Using in silico analysis, we concluded that c.865A>G (p.Asn289Asp) and c.6427T>C (p.Ser2143Pro) are probably deleterious and c.125A>G (p.Tyr42Cys) is probably neutral. Only one of them has previously been reported in Colombia. We also identified 13 polymorphisms (4 in BRCA1 and 9 in BRCA2), two of them are associated with a moderate increase in breast cancer risk (BRCA2 c.1114A>C and c.875566T>C).
Conclusion: According to our results, the Colombian pacific population presents diverse mutational spectrum for BRCA genes that differs from the findings in other regions in the country.
Authors
Downloads
Keywords
- Hereditary Breast and Ovarian Cancer Syndrome
- BRCA1
- BRCA2
- Germ-line mutations
- Colombia
Author Biographies
, Human Molecular Genetics Lab, Departamento de Biología, Universidad del Valle
Universidad del Valle, Departamento de Biología, Human Molecular Genetics Lab, Cali, Colombia
https://orcid.org/0000-0001-7013-1952
, Human Molecular Genetics Lab, Departamento de Biología, Universidad del Valle
Universidad del Valle, Departamento de Biología, Human Molecular Genetics Lab, Cali, Colombia
, Human Molecular Genetics Lab, Departamento de Biología, Universidad del Valle
Universidad del Valle, Departamento de Biología, Human Molecular Genetics Lab, Cali, Colombia
https://orcid.org/0000-0003-2568-2629References
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136(5):E359-86. DOI: 10.1002/ijc.29210. https://doi.org/10.1002/ijc.29210
Bravo LE, Collazos T, Collazos P, García LS, Correa P. Trends of cancer incidence and mortality in Cali, Colombia 50 years experience. Colomb Med (Col). 2012; 43(4):246-55. DOI: 10.25100/cm.v43i4.1266.BRCA1 and BRCA2 mutations in a sample of breast and ovarian cancer families from the Colombian pacific https://doi.org/10.25100/cm.v43i4.1266
Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994; 266(5182):66-71. DOI: 10.1126/science.7545954. https://doi.org/10.1126/science.7545954
Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995; 378(6559):789-92. DOI: 10.1038/378789a0. https://doi.org/10.1038/378789a0
Barnes DR, Antoniou AC. Unravelling modifiers of breast and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: update on genetic modifiers. J Intern Med. 2012; 271:331-43. DOI: 10.1111/j.1365-2796.2011.02502.x. https://doi.org/10.1111/j.1365-2796.2011.02502.x
Thacker J. The RAD51 gene family, genetic instability and cancer. Cancer Lett. 2005; 219(2):125-35. DOI: 10.1016/j.canlet.2004.08.018. https://doi.org/10.1016/j.canlet.2004.08.018
Levy-Lahad E, Lahad A, Eisenberg SA. A Single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers. Proc Natl Acad Sci USA. 2001; 98(6):3232-6. DOI: 10.1073/pnas.051624098. https://doi.org/10.1073/pnas.051624098
Didraga MA, van Beers EH, Joosse SA Brandwijk KI, Oldenburg RA, Wessels LF, et al. A non-BRCA1/2 hereditary breast cancer sub-group defined by aCGH profiling of genetically related patients. Breast Cancer Res Treat. 2011;130(2):425-36. DOI: 10.1007/s10549-011-1357-x https://doi.org/10.1007/s10549-011-1357-x
Balmaña J, Díez O, Rubio IT, Cardoso F. BRCA in breast cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2011;22(Suppl 6): vi31-vi34. DOI: 10.1093/annonc/mdr37310. Ashton-prolla P, Vargas FR. Prevalence and impact of founder mutations in hereditary breast cancer in Latin America. Genet Mol Biol. 2014;37(1 Suppl):234-40. DOI: 10.1590/S1415-47572014000200009 https://doi.org/10.1590/S1415-47572014000200009
Rojas W, Parra MV, Campo O, Caro MA, Lopera JG, Arias W, et al. Genetic make up and structure of Colombian populations by means of uniparental and biparental DNA markers. Am J Phys Anthropol. 2010;143(1):13-20. DOI: 10.1002/ajpa.21270 https://doi.org/10.1002/ajpa.21270
Torres D, Rashid MU, Gil F, Umana A, Ramelli G, Robledo JF, et al. High proportion of BRCA1/2 founder mutations in Hispanic breast/ovarian cancer families from Colombia. Breast Cancer Res Treat. 2007;103(2):225-32. DOI: 10.1007/s10549-006-9370-1 https://doi.org/10.1007/s10549-006-9370-1
Sanabria MC, Muñoz G, Vargas CI. Análisis de las mutaciones más frecuentes del gen BRCA1 (185delAG y 5382insC) en mujeres con cáncer de mama en Bucaramanga, Colombia. Biomédica. 2009;29:61-72. DOI: 10.7705/biomedica.v29i1.42 https://doi.org/10.7705/biomedica.v29i1.42
Torres D, Umaña A, Robledo JF, Caicedo JJ, Quintero E, Orozco A, et al. Estudio de factores genéticos para cáncer de mama en Colombia. Universitas Medica. 2009;50(3):297-301.
Rodríguez AO, Llacuachaqui M, Pardo GG, Royer R, Larson G, Weitzel JN, et al. BRCA1 and BRCA2 mutations among ovarian cancer patients from Colombia. Gynecol Oncol. 2012;124:236-43. DOI: 10.1016/j.ygyno.2011.10.027. https://doi.org/10.1016/j.ygyno.2011.10.027
Londoño-Hernández JE, Llacuachaqui M, Palacio GV, Figueroa JD, Madrid J, Lema M, et al. Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from medellín, Colombia. Hered Cancer Clin Pract. 2014;12:11-15. DOI: 10.1186/1897-4287-12-11. https://doi.org/10.1186/1897-4287-12-11
Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988;16(3):1215. DOI: 10.1093/nar/16.3.1215. https://doi.org/10.1093/nar/16.3.1215
Barker DF. Direct genomic multiplex PCR for BRCA1 and application to mutation detection by single-strand conformation and heteroduplex analysis. Hum Mutat. 2000;16(4):334-44. DOI: 10.1002/1098-1004(200010)16:4<334::AID-HUMU6>3.0.CO;2-6. https://doi.org/10.1002/1098-1004(200010)16:4<334::AID-HUMU6>3.0.CO;2-6
Orita M, Iwahana H, Kanazawat H, Hayashi K, Sekiya T. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci USA. 1989;86:2766-70. DOI: 10.1073/pnas.86.8.2766. https://doi.org/10.1073/pnas.86.8.2766
Naranjo J, Posso A, Cárdenas H, Muñoz JE. Detección de variantes alélicas de la kappa-caseína en bovinos Hartón del Valle. Rev Acta Agronóm. 2007;56(1):43-8.
Théry JC, Krieger S, Gaildrat P, Révillion F, Buisine M-P, Killian A, et al. Contribution of bioinformatics predictions and functional splicing assays to the interpretation of unclassified variants of the BRCA genes. Eur J Hum Genet. 2011;19(10):1052-8. DOI :10.1038/ejhg.2011.100. https://doi.org/10.1038/ejhg.2011.100
Arias-Blanco JF, Ospino-Durán EA, Restrepo-Fernández CM, Guzmán-AbiSaab L, Fonseca-Mendoza DJ, Ángel-Guevara DI, et al. Frecuencia de mutación y de variantes de secuencia para los genes BRCA1 y BRCA2 en una muestra de mujeres colombianas con sospecha de síndrome de cáncer de mama hereditario: serie de casos. Rev Colomb Obstet Ginecol. 2015;66(4):287-96. DOI: 10.18597/rcog.294.BRCA1 and BRCA2 mutations in a sample of breast and ovarian cancer families from the Colombian pacific https://doi.org/10.18597/rcog.294
de Oliveira ES, Soares BL, Lemos S, Rosa RCA, Rodrigues AN, Barbosa LA, dos Santos LL. Screening of the BRCA1 gene in Brazilian patients with breast and/or ovarian cancer via high-resolution melting reaction analysis. Familial Cancer. 2016; 15(2): 173-181. DOI: 10.1007/s10689-015-9858-0 https://doi.org/10.1007/s10689-015-9858-0
Solano A, Aceto G, Delettieres D, Veschi S, Neuman M, Alonso E, et al. BRCA1 and BRCA2 analysis of Argentinean breast/ovarian cancer patients selected for age and family history highlights a role for novel mutations of putative south-American origin. Springerplus. 2012;1:20. DOI: 10.1186/2193-1801-1-20. https://doi.org/10.1186/2193-1801-1-20
Lara K, Consigliere N, Pérez J, Porco A. BRCA1 and BRCA2 mutations in breast cancer patients from Venezuela. Biol Res. 2012;45:117-30. DOI: 10.4067/S0716-97602012000200003 https://doi.org/10.4067/S0716-97602012000200003
Ruiz-Flores P, Sinilnikova OM, Badzioch M, Calderon-Garcidueñas a L, Chopin S, Fabrice O, et al. BRCA1 and BRCA2 mutation analysis of early-onset and familial breast cancer cases in Mexico. Hum Mutat. 2002;20(6):474-5. DOI: 10.1002/humu.9084 https://doi.org/10.1002/humu.9084
Dufloth RM, Carvalho S, Heinrich J K, Shinzato J Y, dos Santos CC, Zeferino LC,et al. Analysis of BRCA1 and BRCA2 mutations in Brazilian breast cancer patients with positive family history. Sao Paulo Med J. 2005;123(4):192-7. DOI: 10.1590/S1516-31802005000400007 https://doi.org/10.1590/S1516-31802005000400007
.28. Salas A, Acosta A, Alvarez-Iglesias V, Cerezo M, Phillips C, Lareu M V, et al. The mtDNA ancestry of admixed Colombian populations. Am. J. Hum. Biol. 2008;20(5): 584-91. DOI: 10.1002/ajhb.20783. https://doi.org/10.1002/ajhb.20783
Tommasi S, Pilato B, Pinto R, Monaco A, Bruno M, Campana M, et al. Molecular and in silico analysis of BRCA1 and BRCA2 variants. Mutat Res Mol Mech. 2008;644(1-2):64-70. DOI: 10.1016/j.mrfmmm.2008.07.005. https://doi.org/10.1016/j.mrfmmm.2008.07.005
Mondal G, Rowley M, Guidugli L, Wu J, Pankratz VS, Couch FJ. BRCA2 localization to the midbody by filamin a regulates CEP55 signaling and completion of cytokinesis. Dev Cell. 2012;23:137-52. DOI: 10.1016/j.devcel.2012.05.008. https://doi.org/10.1016/j.devcel.2012.05.008
Agromayor M, Martin-Serrano J. Knowing when to cut and run: mechanisms that control cytokinetic abscission. Trends Cell Biol.; 2013;23(9):433-41. DOI: 10.1016/j.tcb.2013.04.006. https://doi.org/10.1016/j.tcb.2013.04.006
Seymour I J, Casadei S, Zampiga V, Rosato S, Danesi R, Falcini F, et al. Disease family history and modification of breast cancer risk in common BRCA2 variants. Oncol Rep. 2008;19:783-6. DOI: 10.3892/or.19.3.783. https://doi.org/10.3892/or.19.3.783
Goldgar D E, Easton D F, Deffenbaugh A M, Monteiro ANA, Tavtigian S V, Couch FJ, et al. Integrated evaluation of DNA sequence variants of unknown clinical significance. Am J Hum Genet. 2004;75:535-44. DOI: 10.1086/424388 https://doi.org/10.1086/424388
Wu K, Hinson S R, Ohashi A, Farrugia D, Wendt P, Tavtigian S V, et al. functional evaluation and cancer risk assessment of BRCA2 unclassified variants. Cancer Res. 2005;65(2):417-426.
Kuznetsov S G, Liu P, Sharan S K. Mouse embryonic stem cell-based functional assay to evaluate mutations in BRCA2. Nat Med. 2008;14(8):875-81. DOI: 10.1038/nm.1719 https://doi.org/10.1038/nm.1719
Scully R, Chen J, Plug A, Xiao Y, Weaver D, Feunteun J, et al. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell. 1997;88:265-75. DOI: 10.1016/S0092-8674(00)81847-4. https://doi.org/10.1016/S0092-8674(00)81847-4
Caestecker KW, Van de Walle GR. The role of BRCA1 in DNA double-strand repair: Past and present. Exp Cell Res. 2013;319(5):575-87. DOI: 10.1016/j.yexcr.2012.11.013. https://doi.org/10.1016/j.yexcr.2012.11.013
Durocher F, Shattuck-eidens D, Mcclure M, Labrie F, Skolnick MH, Goldgar DE, et al. Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations. Hum Mol Genet. 1996;5(6):835-42. DOI: 10.1093/hmg/5.6.835. https://doi.org/10.1093/hmg/5.6.835
Arnold N, Peper H, Bandick K, Kreikemeier M, Karow D, Teegen B, et al. Establishing a control population to screen for the occurrence of nineteen unclassified variants in the BRCA1 gene by denaturing high-performance liquid chromatography. J Chromatogr B. 2002;782(1-2):99-104. DOI: 10.1016/S1570-0232(02)00696-7. https://doi.org/10.1016/S1570-0232(02)00696-7
De La Hoya M, Diaz-Rubio E, Calde T. Denaturing gradient gel electrophoresis-based analysis of loss of heterozygosity distinguishes nonobvious, deleterious BRCA1 variants from nonpathogenic polymorphisms. Clin Chem. 1999;45(11):2028-30. https://doi.org/10.1093/clinchem/45.11.2028
Infante M, Duran M, Esteban-Cardeñosa E, Miner C, Velasco E. High proportion of novel mutations of BRCA1 and BRCA2 in breast/ovarian cancer patients from Castilla-León (central Spain). J Hum Genet. 2006;51:611-617. DOI: 10.1007/s10038-006-0404-7. https://doi.org/10.1007/s10038-006-0404-7
Claes K, Poppe B, Coene I, Paepe AD, Messiaen L. BRCA1 and BRCA2 germline mutation spectrum and frequencies in Belgian breast/ovarian cancer families. Br J Cancer. 2004;90(6):1244-51. DOI: 10.1038/sj.bjc.6601656.BRCA1 and BRCA2 mutations in a sample of breast and ovarian cancer families from the Colombian pacific https://doi.org/10.1038/sj.bjc.6601656
Tavtigian S V, Deffenbaugh A M, Yin L, Judkins T, Scholl T, Samollow PB, et al. Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. J Med Genet. 2006;43(4):295-305. DOI: 10.1136/jmg.2005.033878. https://doi.org/10.1136/jmg.2005.033878
Abkevich V, Zharkikh A, Deffenbaugh A M, Frank D, Chen Y, Shattuck D, et al. Analysis of missense variation in human BRCA1 in the context of interspecific sequence variation. J Med Genet 2004;41(7):492-507. DOI: 10.1136/jmg.2003.015867. https://doi.org/10.1136/jmg.2003.015867
Teare MD, Cox A, Shorto J, Anderson C, Bishop DT, Cannings C. Heterozygote excess is repeatedly observed in females at the BRCA2 locus N372H. J Med Genet. 2004;41(7):523-28. DOI: 10.1136/jmg.2003.017293. https://doi.org/10.1136/jmg.2003.017293
Wen-Qiong X, Yong-Qiao H, Jin-Hong Z, Jian-Qun M, Jing H, Wei-Hua J. Association of BRCA2 N372H polymorphism with cancer susceptibility: a comprehensive review and meta-analysis. Sci Rep. 2014;4:6791. DOI: 10.1038/srep06791. https://doi.org/10.1038/srep06791
Kawahara M, Sakayori M, Shiraishi K, Nomizu T, Takeda M, Abe R, et al. Identification and evaluation of 55 genetic variations in the BRCA1 and the BRCA2 genes of patients from 50 Japanese breast cancer families. J Hum Genet. 2004;49:391-5. DOI: 10.1007/s10038-004-0160-5. https://doi.org/10.1007/s10038-004-0160-5
Gross E, Arnold N, Goette J, Schwarz-Boeger U, Kiechle M. A comparison of BRCA1 mutation analysis by direct sequencing, SSCP and DHPLC. Hum Genet. 1999;105:72-8. DOI: 10.1007/s004399900092. https://doi.org/10.1007/s004399900092
Briceño-Balcazar I, Gómez-Gutiérrez A, Díaz-Dussán NA, Noguera-Santamaría MC, Díaz-Rincón D, Casas-Gómez MC. Mutational spectrum in breast cancer associated BRCA1 and BRCA2 genes in Colombia. Colomb Med (Col). 2017;48(2):58-63. DOI: 10.25100/cm.v48i2.1867. https://doi.org/10.25100/cm.v48i2.1867
Cock-Rada AM, Ossa CA, Garcia HI, Gomez LR. A multi-gene panel study in hereditary breast and ovarian cancer in Colombia. Fam Cancer. 2018;17(1):23-30. DOI: 10.1007/s10689-017-0004-z. https://doi.org/10.1007/s10689-017-0004-z
Avila S, Briceño I, Gomez A. Genetic population analysis of 17 Y-chromosomal STRs in three states (Valle del Cauca, Cauca and Nariño) from Southwestern Colombia. J Forensic Leg Med. 2009;16(4):204-11. DOI: 10.1016/j.jflm.2008.12.002.BRCA1 and BRCA2 mutations in a sample of breast and ovarian cancer families from the Colombian pacific https://doi.org/10.1016/j.jflm.2008.12.002
Copyright (c) 2019 Universidad del Valle
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The copy rights of the articles published in Colombia Médica belong to the Universidad del Valle. The contents of the articles that appear in the Journal are exclusively the responsibility of the authors and do not necessarily reflect the opinions of the Editorial Committee of the Journal. It is allowed to reproduce the material published in Colombia Médica without prior authorization for non-commercial use
